MESA, ARIZONA / ACCESS Newswire / September 23, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced the launch of its AI Facial Health Risk Estimator, a groundbreaking technology that leverages advanced facial imaging to provide early risk detection for cardiovascular disease, one of the leading causes of death worldwide.
The system uses deep neural networks trained on biometric signatures such as micro-wrinkle density, skin elasticity, and tone variations to generate a real-time estimate of biological age. By comparing biological age against chronological age, the platform identifies cardiovascular predisposition and risk factors before clinical symptoms emerge.
“Cardiovascular disease prevention has always depended on invasive testing and delayed symptom recognition,” said Marshall Perkins, CEO of MDCE. “Our AI system will deliver a non-invasive, accessible solution that empowers patients to detect early problems with their heart health.”
Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com
About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC PINK: MDCE) develops AI-powered health solutions that enable early detection, preventive screening, and personalized wellness insights for systemic, ocular, and dermatological conditions.
Safe Harbor Statement:
This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially.
Contact:
Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…